Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies for the treatment of diabetes, ophthalmic diseases, pulmonary arterial hypertension and pediatric growth hormone deficiency, among others. The Company�s lead product candidate, TransCon human growth hormone (TransCon hGH), is indicated for the treatment of growth hormone deficiency (GHD), and other indications. The Company�s other products are TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab. TransCon Treprostinil is indicated for the treatment of pulmonary arterial hypertension, while TransCon Insulin and TransCon Peptide are indicated for the treatment of diabetes. TransCon Ranibizumab is used for the treatment of ophthalmic diseases.